Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Phase III Data for Relapsed/Refractory Myeloma

December 6th 2017

Key Studies in Newly-Diagnosed Multiple Myeloma

December 6th 2017

Daratumumab for Smoldering Myeloma

December 6th 2017

KRd for High-Risk Smoldering Myeloma

December 6th 2017

AML Studies: BiTE Antibodies and Age for Transplant

December 6th 2017

AML Studies: FLT3 Inhibitors

December 6th 2017

Acute Myeloid Leukemia: Novel Targeted Therapies

December 6th 2017

NHL Studies: CAR T Therapy, Rituximab Maintenance, & PD-L1

December 6th 2017

New Data for Mantle Cell Lymphoma

December 6th 2017

Hodgkin Lymphoma: Upfront Brentuximab Vedotin + AVD

December 6th 2017

Pre-Conference Perspectives on Hematologic Malignancies

December 6th 2017

Triplet Therapy With Selinexor Tested in Myeloma

December 4th 2017

Selinexor, a novel drug that targets a tumor-suppressor “cargo” protein mechanism, is being investigated in patients with relapsed/refractory multiple myeloma who have received 1 to 3 prior treatment regimens.

Expert Discusses Novel Treatment Options in Multiple Myeloma

December 4th 2017

Sameh Mikhail, MD, discusses the promise of daratumumab, as well as the potential of medical marijuana to curb the adverse events seen with potent anticancer drugs.

Dr. Mikhail on Ongoing Trials in Multiple Myeloma

December 2nd 2017

Sameh Mikhail, MD, medical oncologist, The Mark H. Zangmeister Cancer Center, discussing ongoing trials for patients with multiple myeloma.

Novel Agents, Combos Excite in Multiple Myeloma

November 28th 2017

Dan T. Vogl, MD, highlights the potential with CAR T-cell therapy in the multiple myeloma paradigm.

Dr. Kumar Discusses Genetic Abnormalities in Myeloma

November 22nd 2017

Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses genetic abnormalities in multiple myeloma.

FDA Approval Sought for Frontline Daratumumab in Myeloma

November 22nd 2017

A supplemental biologics license application has been submitted to the FDA for daratumumab for use in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation.

FDA Grants BCMA CAR T-Cell Therapy Breakthrough Designation in Myeloma

November 17th 2017

The FDA has granted the the anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy bb2121 a breakthrough therapy designation for previously treated patients with relapsed/refractory multiple myeloma.

Dr. Hofmeister Discusses Checkpoint Inhibitors in Myeloma

November 16th 2017

Craig Hofmeister, MD, associate professor, The Ohio State University Comprehensive Cancer Center, discusses checkpoint inhibitors in multiple myeloma.

Dr. Chari on Comparing Agents in Multiple Myeloma

November 14th 2017

Ajai Chari, MD, associate professor, Mount Sinai Hospital, discusses comparing agents in multiple myeloma.